Business Context and Reporting Period
Company: eXegenics Inc. (renaming to Opko Corporation)
Filing Type: Form 8-K (Current Report)
Date: March 27, 2007
Event: Completion of a reverse acquisition and merger transaction. eXegenics, previously a shell company with no operations, merged with and acquired Froptix Corporation and Acuity Pharmaceuticals, Inc. The transaction was structured as a reverse acquisition where Froptix was deemed the accounting acquirer of eXegenics, followed by the acquisition of Acuity. The combined entity is a clinical-stage biopharmaceutical company focused on ophthalmic diseases, specifically targeting wet age-related macular degeneration (Wet AMD) with its lead candidate, bevasiranib.
Key Financial Metrics
Revenue: $0. The company has no product revenue and does not expect to generate revenue from product sales in the foreseeable future.
Profitability: The company has a history of operating losses.
- Acuity Net Loss (2006): $11,092,000
- Froptix Net Loss (Inception to Dec 31, 2006): $877,000
- Accumulated Deficit (Combined): Approximately $57,050,000 (eXegenics historical) plus Acuity's deficit of $32,708,748.
Cash and Liquidity:
- Cash on Hand (Post-Merger): Approximately $16,250,000.
- Debt: Assumed a $4,000,000 obligation under a line of credit with The Frost Group, LLC. The line was amended to provide an additional $8,000,000 in available borrowings (Total capacity: $12,000,000). Interest rate is 10% annually.
- Contractual Obligations: Total principal contractual obligations of $13,625,000, including long-term debt, operating leases, and research license agreements.
Capital Structure (Post-Merger):
- Common Stock Outstanding: 113,116,350 shares.
- Preferred Stock: 457,584 shares of Series C preferred stock issued (convertible into 45,758,400 common shares).
- Warrants: 21,144,114 warrants granted to former stockholders of Froptix and Acuity, plus 4,000,000 warrants granted to The Frost Group, LLC.
Material Changes vs. Prior Period
Operational Shift: eXegenics transitioned from a shell company with no operations to an active clinical-stage biopharmaceutical company with two operating subsidiaries (Froptix and Acuity).
Acquisition Costs: The company incurred normal acquisition-related costs. The transaction involved significant issuance of equity (common stock, preferred stock, and warrants) rather than cash consideration.
Debt Assumption: The company assumed Acuity's existing $4,000,000 debt obligation and secured an additional $8,000,000 in borrowing capacity, a material change from eXegenics' prior debt-free status.
Accounting Treatment: The transaction was accounted for as a reverse acquisition (Froptix acquiring eXegenics) followed by a business combination (eXegenics acquiring Acuity). This resulted in the elimination of eXegenics' historical equity and the recognition of Acuity's historical financials as the primary basis for the combined entity.
Guidance, Outlook, and Risks
Outlook:
- Product Pipeline: The company plans to begin Phase III clinical trials for bevasiranib in 2007 following successful Phase II results (CARE trial) showing safety and efficacy in Wet AMD.
- Future Funding: The company expects to incur substantial losses for the foreseeable future and will require significant additional funding to complete clinical trials and commercialize products. No specific revenue guidance is provided.
- Listing: The company intends to apply for listing on the American Stock Exchange.
Management Commentary: Management believes bevasiranib addresses the underlying source of VEGF production, potentially offering advantages over existing therapies. They plan to leverage RNAi technology for other ophthalmic indications including Dry AMD, retinitis pigmentosa, and viral conjunctivitis.
Risks and Contingencies:
- Regulatory Risk: No products are approved; Phase III trials may fail or not satisfy FDA requirements.
- Liquidity Risk: The company has no product revenue and relies on equity/debt financing. Failure to secure funding could force delays or elimination of clinical trials.
- Technology Risk: RNAi technology is unproven in the clinical medical community; early trial results do not guarantee future success.
- Competition: Highly competitive market with larger pharmaceutical companies (e.g., Genentech, Pfizer) having greater resources.
- Intellectual Property: Reliance on third-party licenses (University of Pennsylvania, University of Illinois, etc.) and potential patent litigation.
- Related Party Transactions: Significant ownership and credit facilities are controlled by The Frost Group, LLC, which includes the CEO and Chairman.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $16.25 million cash balance and $8 million credit line to fund Phase III trials for bevasiranib without immediate dilution.
- Phase III Design: Confirm the specific endpoints and timeline for the upcoming Phase III clinical trials for bevasiranib.
- Related Party Terms: Review the specific terms of the $12 million line of credit with The Frost Group, LLC, including covenants and the 10% interest rate.
- Escrow and Lock-up: Note that 11.5% of shares issued in the merger are held in escrow until March 2008, and approximately 68% of outstanding shares are subject to two-year lock-up agreements.
- License Obligations: Assess the financial impact of milestone payments and royalty obligations under licenses with the University of Pennsylvania, University of Illinois, and Pathogenics, Inc.
- Stock Dilution: Evaluate the potential dilution from the 21+ million warrants and 457,584 shares of convertible Series C preferred stock outstanding.